MLTX Fail-to-Deliver
MoonLake Immunotherapeutics (MLTX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $1.36B, listed on NASDAQ, employing roughly 100 people, carrying a beta of 1.01 to the broader market. MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. Led by Jorge Santos da Silva, public since 2020-10-20.
Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.
- Latest Date
- 2026-04-20
- Latest FTD Quantity
- 10.5K
- Latest Price
- $18.34
- 30-Day Avg FTD
- 155.0K
- 30-Day Total FTD
- 4.7M
Showing 30 days of SEC fail-to-deliver data for MoonLake Immunotherapeutics.
Learn how fails-to-deliver is reported and how to read the data →
Frequently asked MLTX fail to deliver questions
- What is the latest MLTX fail-to-deliver count?
- As of Apr 20, 2026, MoonLake Immunotherapeutics (MLTX) fail-to-deliver quantity is 10.5K shares, with a 30-day average of 155.0K shares. The SEC publishes FTD data twice monthly: first-half data at month-end, second-half around the 15th of the following month.
- What is the FTD aggregate net balance?
- FTD figures represent the aggregate net balance in NSCC's Continuous Net Settlement (CNS) system, not the gross failed-share count. The published numbers run 2-6 weeks stale relative to the underlying settlement date.
- How do MLTX FTDs affect options pricing?
- Persistent FTDs flag hard-to-borrow conditions that distort put-call parity: in HTB names, synthetic long stock (long call + short put at the same strike) trades below the frictionless-parity price by approximately the borrow rebate. The discount equals the lending revenue forgone by holding the synthetic instead of actual shares. Reg SHO threshold-list inclusion follows from sustained FTD persistence.